Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet

The scientific premise of this proposal is that established or long-term (≥ 12 months) Modified Atkins diet (MAD) use in AWE influences atherosclerotic cardiovascular disease (ASCVD) risk and can be modified to reduce dyslipidemia when observed. Hence, the overarching goals of this proposal are to explore the safety and feasibility of dyslipidemia management strategies to reduce ASCVD risk in AWE on MAD without increasing seizure risk. This study will collect data before and after randomly assigned interventions to reduce LDL in AWE on long-term MAD recruited from patients receiving clinical care in the Johns Hopkins Adult Epilepsy Diet Center.

AWE with dyslipidemia on long-term MAD will be randomized 1:1 to either MAD modification (10% reduction of dietary energy from saturated fat, replaced with poly-unsaturated fat ) or moderate-intensity statin use (atorvastatin 10mg) for 12 weeks.

Inclusion criteria

• Modified Atkins Diet use ≥ 12 months
• Dyslipidemia based on American College of Cardiology/American Heart Association guidelines (i.e., LDL ≥190 mg/dL, 10-year ASCVD risk ≥5% with risk enhancers, etc.)
• 18 years of age or older
• Body mass index (BMI) > 18.5
• Stable anti-seizure medication regimen for > 1 month.

Exclusion criteria

• < 18 years of age
• Body mass index (BMI) < 18.5
• Changes in anti-seizure medication regimen < 1 month prior to participation
• Known ASCVD (history of acute coronary syndrome, myocardial infarction, angina, stroke, transient ischemic attack, or peripheral artery disease)
• Current statin medication use
• Prior serious adverse response to atorvastatin or other statin medications
• Uncorrected carnitine deficiency
• Pregnancy